Regeneron Pharmaceuticals’ investigational gene therapy DB-OTO improved hearing in two young children with “profound genetic deafness” since birth, according to the company’s Wednesday oral presentation at the 2024 American Society of Gene & Cell Therapy annual meeting in Baltimore.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,